Evidence map›Paper›PMID 37849487›Full record

ArticleFrontiers in medicine2023

High-Flow Nasal Cannula oxygen therapy in COVID-19: retrospective analysis of clinical outcomes - single center experience.

Dušanka Obradović, Aleksandra Milovančev, Aleksandra Plećaš Đurić, Stanislava Sovilj-Gmizić, Vladimir Đurović, Jovica Šović, Miloš Đurđević, Stevan Tubić, Jelena Bulajić, Milena Mišić and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Dušanka ObradovićFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Aleksandra MilovančevFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Aleksandra Plećaš ĐurićFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Stanislava Sovilj-GmizićInstitute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Vladimir ĐurovićClinic of Nephrology and Clinical Immunology, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Jovica ŠovićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Miloš ĐurđevićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Stevan TubićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Jelena BulajićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Milena MišićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Jovana JojićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Miroslava PušaraUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Ivana LazićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Mladen ĐurkovićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Renata Bek PupovacUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Aleksandra VulićUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Marija JozingUrgent Care Center, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Klinički centar Vojvodine · RSUniversity of Novi Sad · RSInstitute for Pulmonary Diseases of Vojvodina · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: High-Flow Nasal Cannula (HFNC) oxygen therapy emerged as the therapy of choice in COVID-19-related pneumonia and moderate to severe acute hypoxemic respiratory failure (AHRF). HFNC oxygen therapy in COVID-19 has been recommended based its use to treat AHRF of other etiologies, and studies on assessing outcomes in COVID-19 patients are highly needed. This study aimed to examine outcomes in COVID-19 patients with pneumonia and severe AHRF treated with HFNC. Materials and methods: The study included 235 COVID-19 patients with pneumonia treated with HFNC. Data extracted from medical records included demographic characteristics, comorbidities, laboratory parameters, clinical and oxygenation status, clinical complications, as well as the length of hospital stay. Patients were segregated into two groups based on their oxygen therapy needs: HDU group, those who exclusively required HFNC and ICU group, those whose oxygen therapy needed to be escalated at some point of hospital stay. The primary outcome was the need for respiratory support escalation (noninvasive or invasive mechanical ventilation) and the secondary outcome was the in-hospital all-cause mortality. Results: The primary outcome was met in 113 (48%) of patients. The overall mortality was 70%, significantly higher in the ICU group [102 (90.2%) vs. 62 (50.1%), Conclusion: High-Flow Nasal Cannula oxygen therapy is a safe type of respiratory support in patients with COVID-19 pneumonia and acute hypoxemic respiratory failure with significantly less possibility for emergence of intrahospital infections. In 52% of patients, HFNC was successful in treating AHRF in COVID-19 patients. Overall, mortality in COVID-19 pneumonia with AHRF is still very high, especially in patients treated with noninvasive/invasive mechanical ventilation.

Indexed as

acute hypoxemic respiratory failureclinical outcomesCOVID-19High-Flow Nasal Cannula oxygen therapyintensive care unit

Identifiers

PMID37849487
PMCPMC10577378
OpenAlexW4387305466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.